NEURACAP
Sector OutlookPublished · 20 pages · Free to read

Regenerative Medicine Sector Outlook — September 2026

This report covers the Regenerative Medicine sector as of September 2026 — implants, instrumentation, therapeutics and adjacent models — using EV/EBITDA (CY2027E) as the primary valuation lens alongside precedent transaction evidence, for teams assessing portfolio strategy and positioning.

For information only. Not an appraisal or a fairness opinion.

What moved since: Regenerative Medicine M&A update, 14–28 September 2026

Key figures

Sector median
10.0x
EV/EBITDA (CY2027E), 4 of 8 rated
Premium tier multiple
16.7x
EV/EBITDA (CY2027E)
Discount tier multiple
2.3x
EV/EBITDA (CY2027E)
Acelity precedent value
$6.7B
15.2x EV/EBITDA at announcement

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE

Regenerative Medicine: Earnings Quality Separates Value

This report shows how profit visibility, reimbursement durability and platform breadth distinguish the sector.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice

1

1 / 20

Executive summary

Regenerative medicine does not trade as one business model: commercial implant, scaffold and instrumentation platforms carry the clearest forward profit support, while therapeutics depend more on clinical and regulatory milestones. Priced companies span 2.3x to 16.7x EV/EBITDA (CY2027E), with a 10.0x median, and similar margins sit at very different points in that range. Reimbursement durability, commercial consistency and platform breadth help explain where the premium concentrates.

Key findings

  • Only 4 of 8 companies carry a forward EV/EBITDA (CY2027E) estimate.
  • Priced multiples span 2.3x to 16.7x EV/EBITDA (CY2027E), median 10.0x.
  • Similar margins (30% vs 31%) sit at opposite ends of the valuation range.
  • Acelity, Inc. was valued at $6.7B and 15.2x EV/EBITDA at announcement.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE

    Cover slide introducing the Regenerative Medicine sector outlook as of September 2026.

    We open on the Regenerative Medicine sector as of 2026-09-28, framed on EV/EBITDA (CY2027E) as the primary valuation lens. The pages that follow show where profit visibility and buyer appetite align, and where they diverge, so the full valuation picture is on the table from the start.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › REGENERATIVE MEDICINE Regenerative Medicine: Earnings Quality Separates Value This report shows how profit visibility, reimbursement durability and platform breadth distinguish the sector. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    Contents page listing the report's five sections plus the appendix.

    We structure this report so the Bottom Line lands first, then build out the landscape, valuation, precedent transactions and strategic implications behind it. A reader who stops after section one still leaves with the full story, with the appendix ready for anyone who wants to trace a figure further. That ordering lets us move quickly through the evidence without losing the thread.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Regenerative Medicine Contains Distinct Business Models with Very Different Valuation Support 02 The Landscape Commercial Platforms Carry the Valuation Evidence 03 Valuation & Situations The Premium Survives a Forward Profit Lens 04 Precedent Transactions Precedent Transactions Favour Established Wound and Tissue Platforms 05 Strategic Implications The Operating Agenda Is Revenue Quality, Portfolio Breadth and Consistent Conversion 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Regenerative Medicine Splits Across Implants, Instrumentation, Therapeutics and Adjacent Models

    Bottom-line summary showing how regenerative medicine splits across implants, instrumentation, therapeutics and adjacent models.

    Only 4 of 8 companies carry a forward EV/EBITDA (CY2027E) estimate, and the median across that priced set sits at 10.0x. The priced range runs from 2.3x up to 16.7x, wide enough to separate business models within the same sector. Because this set is profitable, EV/EBITDA leads and EV/Revenue serves only as a cross-check. That combination of profit visibility and range is the starting point for everything else in this report.

    Everything on this page

    01 · THE BOTTOM LINE Regenerative Medicine Splits Across Implants, Instrumentation, Therapeutics and Adjacent Models The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (4 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners also quote EV / Revenue in this industry; this set is profitable (median forward EBITDA margin 25%, 6 of 8 names with a meaningful EBITDA), so EV / EBITDA leads and EV / Revenue is the cross-check. Qualitative characterisations are NeuraCap views. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 A Profit Lens Covers Only Half the Set Only 4 of 8 companies carry a forward EV / EBITDA estimate. The middle of that priced set is 10.0x, and the lens reflects meaningful forward profit rather than revenue alone. 2 The Valuation Range Leaves Room to Separate The premium end stands at 16.7x versus 2.3x at the discount end. Because both are forward profit multiples, the gap already reflects forecast earnings and points to different views of durability. 3 Similar Margins Sit at Opposite Ends LeMaitre Vascular, Inc. [LMAT] carries a 30% margin at the premium end, while SANUWAVE Health Inc. [SNWV] carries a 31% margin at the discount end. Reimbursement durability, channel quality and operating consistency remain important parts of the valuation read. 4 The Transaction Record Points to Buyer Appetite for Scaled Wound Platforms The Acelity, Inc. transaction was valued at $6.7B and 15.2x EV / EBITDA. That precedent shows the price buyers have agreed for a scaled wound platform with established commercial reach. 10.0x Sector median EV/EBITDA CY2027E consensus · 4 rated of 8 companies 16.7x Premium end EV/EBITDA vs 2.3x at the discount end top quartile (n=1) against bottom quartile (n=1) on EV/EBITDA — the spread the report explains 7 Transactions with disclosed terms 23 recorded in this tier · 2 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Section divider introducing the market map on commercial platforms versus therapeutics.

    This section turns to where profit visibility actually sits — with commercial platforms rather than clinical-stage therapeutics. We use the next pages to show how that split shapes the valuation conversation.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Commercial Platforms Carry the Valuation Evidence Implants, biologic scaffolds and repair instrumentation have clearer profit support than clinical-stage therapeutics. 02 of 06 Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Profit Visibility Sits with Commercial Platforms, While Therapeutics Follow a Different Path

    Market map grouping the 8 approved companies by business segment with median EV/EBITDA (CY2027E) per group.

    We group the 8 approved companies by business segment and take the median EV/EBITDA (CY2027E) within each group. Commercial platforms carry visible profit support, while therapeutics follow a different valuation path. This grouping is how we read where the market is willing to price on current earnings versus future potential, so it sets up every comparison that follows.

    Everything on this page

    02 · MARKET MAP Profit Visibility Sits with Commercial Platforms, While Therapeutics Follow a Different Path 8 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 REGENERATIVE IMPLANTS AND BIOLOGIC SCAFFOLD DEVICES 2 cos median 10.0x IART AORT Both names carry forward profit estimates, making this the clearest segment for comparable valuation. GRAFT DELIVERY AND SOFT-TISSUE REPAIR INSTRUMENTATION 2 cos 16.7x · 1 rated LMAT SMTI Commercial access and procedure-based demand matter, but only one name currently carries the lead valuation estimate. CLINICAL-STAGE TISSUE REGENERATION THERAPEUTICS 2 cos no rated names MDXG SRZN Neither name carries the lead valuation estimate, so clinical and regulatory progress frame the story. ADJACENT MODELS 2 cos 2.3x · 1 rated ORGO SNWV The group spans different operating positions and offers limited support for a single segment valuation.

  6. 06
    02 · LANDSCAPE

    Commercial Platforms Can Be Priced on Profit; Therapeutics Still Sit Outside That Lens

    Segment-level view of the approved universe on EV/EBITDA (CY2027E) medians for rated names.

    Commercial platforms can be priced on profit today; therapeutics still sit largely outside that lens. We keep this view to rated names only, so every median reflects real forward estimates rather than a mix of covered and uncovered companies. Full company-level detail sits in the appendix for any name a client wants to check directly.

    Everything on this page

    02 · LANDSCAPE Commercial Platforms Can Be Priced on Profit; Therapeutics Still Sit Outside That Lens Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Regenerative implants and biologic scaffold devices 2 25% 10.0x Integra LifeSciences Holdings Corporation (IART) · Artivion, Inc. (AORT) Profit visibility is established. Integra LifeSciences Holdings Corporation [IART] and Artivion, Inc. [AORT] pair regenerative implants and biologic scaffolds with forward profit estimates. Graft delivery and soft-tissue repair instrumentation 2 25% 16.7x n=1 LeMaitre Vascular, Inc. (LMAT) · Sanara MedTech Inc. (SMTI) Channel execution separates outcomes. LeMaitre Vascular, Inc. [LMAT] and Sanara MedTech Inc. [SMTI] serve procedure-led markets where account productivity, reorder behaviour and care-setting access matter. Clinical-stage tissue regeneration therapeutics 2 25% — MiMedx Group, Inc. (MDXG) · Surrozen, Inc. (SRZN) Milestones frame the value. MiMedx Group, Inc. [MDXG] and Surrozen, Inc. [SRZN] sit outside the lead profit lens, leaving clinical, regulatory and reimbursement progress central to their positioning. Adjacent models 2 25% 2.3x n=1 Organogenesis Holdings Inc. (ORGO) · SANUWAVE Health Inc. (SNWV) Different economics sit together. Organogenesis Holdings Inc. [ORGO] and SANUWAVE Health Inc. [SNWV] bring different product, pathway and commercial characteristics to the adjacent group.

  7. 07
    SECTION 03

    03

    Section divider introducing the valuation section on forward profit pricing.

    We move next into how forward profit pricing separates the peer set. Only half the group carries a rated multiple, yet the priced range still stretches wide, which is exactly where the section picks up.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Premium Survives a Forward Profit Lens Only half the peer set carries a forward EV / EBITDA estimate, but the priced range remains wide. 03 of 06 Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Forward Profit Pricing Separates the Two Ends of the Peer Set

    Ranked EV/EBITDA (CY2027E) multiples for all four rated companies with the sector median marked.

    Across the 4 rated companies, EV/EBITDA (CY2027E) multiples run from 2.3x to 16.7x, with a sector median of 10.0x. Every multiple on this page uses the same CY2027E basis, so the comparison is apples to apples. The tier zones are cut at the rated set's own quartiles, giving a clean read on where each name sits relative to its peers.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Forward Profit Pricing Separates the Two Ends of the Peer Set EV / EBITDA (CY2027E) · all 4 rated companies, sorted descending · sector median 10.0x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (4 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners also quote EV / Revenue in this industry; this set is profitable (median forward EBITDA margin 25%, 6 of 8 names with a meaningful EBITDA), so EV / EBITDA leads and EV / Revenue is the cross-check. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 16.7x CORE · median 10.0x DISCOUNT · median 2.3x Sector median 10.0x WHAT SEPARATES THE TWO ENDS The range remains wide. The premium end is priced at 16.7x, compared with 2.3x at the discount end. Profit alone is insufficient. LeMaitre Vascular, Inc. [LMAT] and SANUWAVE Health Inc. [SNWV] are both profitable, yet they occupy opposite valuation ends. Coverage limits broad conclusions. Only 4 of 8 companies carry the forward estimate used for ranking, so company-specific reimbursement, growth and execution remain central.

  9. 09
    03 · VALUATION DRIVERS

    The Premium Sits Where Profitability Comes with Commercial Durability

    Median EV/EBITDA (CY2027E) split by revenue-growth cohort and by EBITDA-margin cohort.

    We split the rated names by revenue growth and by EBITDA margin, each cut at its own covered median, to see where the premium concentrates. The reading here is association rather than causation — profitability paired with commercial durability tends to sit with stronger multiples. That distinction points to where a client's own commercial evidence, not margin alone, does the work of building the case for a premium.

    Everything on this page

    03 · VALUATION DRIVERS The Premium Sits Where Profitability Comes with Commercial Durability Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=0; slower n=0; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 Similar Margins Can Carry Very Different Valuations LeMaitre Vascular, Inc. [LMAT] posts a 30% margin, while SANUWAVE Health Inc. [SNWV] posts 31%. Their different valuation positions show that margin is one part of the market's assessment. Faster Growth Does Not Map Directly to the Premium LeMaitre Vascular, Inc. [LMAT] carries 10% growth at the premium end, while SANUWAVE Health Inc. [SNWV] carries 26% at the discount end. Within these two names, faster growth is associated with the lower valuation. Coverage Durability Changes the Quality of Revenue Revenue backed by stable coding, payer coverage and evidence presents a different risk profile from revenue exposed to pathway or payment-policy change. Platform Breadth Strengthens Commercial Resilience Products spanning care settings, supported by donor recovery and processing, can reduce dependence on a single product, indication or channel.

  10. 10
    03 · SITUATION MAP

    Margin and Valuation Create Four Different Operating Positions

    Situation map cutting rated names on EV/EBITDA versus the sector median and EBITDA margin versus the covered median.

    We cut the rated set on EV/EBITDA against the 10.0x sector median and on EBITDA margin against the 30% covered median, creating four distinct operating positions. These boundaries are the cohort's own medians, so the map describes where companies sit today rather than recommending any action. It gives a client a structured way to see which quadrant their own profile would land in.

    Everything on this page

    03 · SITUATION MAP Margin and Valuation Create Four Different Operating Positions Cut on EV / EBITDA vs the sector median (10.0x) (rows) and EBITDA margin vs the covered median (30%) (columns) · 1 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Margin Support Above-median multiple · above-median EBITDA margin 1 names LeMaitre Vascular, Inc. (LMAT) Within the three mapped names, LeMaitre Vascular, Inc. [LMAT] sits above both reference lines. The position pairs premium valuation with above-reference profitability. Premium Ahead of Margin Above-median multiple · below-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Margin Without Premium Below-median multiple · above-median EBITDA margin 1 names SANUWAVE Health Inc. (SNWV) Within the three mapped names, SANUWAVE Health Inc. [SNWV] sits below the valuation reference despite an above-reference margin. The position points to factors beyond current profitability. Conversion Still to Prove Below-median multiple · below-median EBITDA margin 1 names Integra LifeSciences Holdings Corporation (IART) Within the three mapped names, Integra LifeSciences Holdings Corporation [IART] sits below both reference lines. Better conversion, growth durability or commercial execution could change that position.

  11. 11
    03 · THE AGENDA

    Growth, Margin and Scale: Three Operating Priorities Associated with Stronger Valuation Support

    Framing of growth, margin and scale as the three operating priorities associated with stronger valuation support.

    We frame growth, margin and scale as the three questions an owner or acquirer should resolve, grounded in the cohort data shown earlier. These are observations rather than recommendations, but they give a structured way to test where a business sits against the same drivers. That structure carries directly into the strategic implications later in this report.

    Everything on this page

    03 · THE AGENDA Growth, Margin and Scale: Three Operating Priorities Associated with Stronger Valuation Support NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Strengthen Reimbursement Durability Focus the portfolio on products with stable coding, broad payer coverage and evidence tied to covered indications. What changes the answer: The answer changes when coverage expansion or payment-policy reform materially changes product economics. Concentrate on Productive Channels Direct resources toward care settings, accounts and products where clinician adoption, reorder behaviour and rep productivity reinforce one another. What changes the answer: The answer changes when distributor reach or a direct sales model produces more durable account economics. Build Breadth Around the Core Evaluate adjacent products, donor recovery capacity and processing capabilities that deepen existing clinician relationships. What changes the answer: The answer changes when an adjacent product adds channel complexity without improving account value or portfolio resilience.

  12. 12
    SECTION 04

    04

    Section divider introducing the precedent transaction record for wound and tissue platforms.

    We now turn to what strategic buyers have actually paid. The transaction record favours established wound and tissue platforms, and the next pages set out that evidence in detail.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Favour Established Wound and Tissue Platforms Strategic buyers have paid across a wide range for channel access, biologic content and scaled operations. 04 of 06 Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    Agreed Valuations in the Transaction Record Vary Widely by Target Type and Deal Size

    Case studies on two of seven transactions with disclosed terms, told with multiples on LTM financials at announcement.

    We highlight 2 of 7 transactions with disclosed terms as case studies, including Acelity, Inc. at $6.7B and 15.2x EV/EBITDA. These deal multiples are LTM at announcement and are not directly comparable to the CY2027E public basis, so we draw no spread between them. What they show instead is the price strategic buyers have agreed for scale and channel access, which frames the strategic questions ahead.

    Everything on this page

    04 · DEAL CASE STUDIES Agreed Valuations in the Transaction Record Vary Widely by Target Type and Deal Size 2 of 7 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 26 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 16 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 May-2019 $6.7B 3M Company Acelity, Inc. Set the Scaled Wound-Platform Benchmark EV / LTM revenue n/a EV / LTM EBITDA 15.2x WHY THE DEAL HAPPENED The transaction suggests a diversified buyer valued a scaled wound platform that could extend an established commercial channel. Product breadth and recurring procedure demand made the asset relevant beyond a single product. HOW THE TARGET WAS VALUED Acelity, Inc. was valued at $6.7B and 15.2x EV / EBITDA. That sits toward the upper end of the transaction record. Aug-2020 $23M SANUWAVE Health, Inc. acquires Celularity, Inc. EV / LTM revenue 1.8x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The completed transaction suggests a buyer saw commercial adjacency between wound-healing systems and Celularity, Inc. The combination brought related offerings closer to the same care pathway. HOW THE TARGET WAS VALUED Celularity, Inc. was valued at $23M and 1.8x EV / Revenue. That provides a revenue benchmark for a smaller adjacent transaction.

  14. 14
    SECTION 05

    05

    Section divider introducing the operating agenda on revenue quality, portfolio breadth and conversion.

    The next section sets out the operating agenda: revenue quality, portfolio breadth and consistent conversion. These are the levers owners can influence directly, and they carry through to how the market prices durability.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS The Operating Agenda Is Revenue Quality, Portfolio Breadth and Consistent Conversion Owners can strengthen their standing through durable coverage, productive channels and disciplined cost structure. 05 of 06 Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    Durable Revenue and Consistent Conversion Sit with the Premium End of the Range

    Strategic implications showing durable revenue and consistent conversion sitting with the premium end of the range.

    We read durable revenue and consistent conversion as the traits that sit with the premium end of the priced range. For owners, that means aligning product mix and investment with coverage durability; for management teams, it means making commercial productivity repeatable; for boards, it means testing build-versus-buy with discipline. These are directional views drawn from the data in this report, framed as questions for the next twelve months.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Durable Revenue and Consistent Conversion Sit with the Premium End of the Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Prioritise Durable Revenue Quality Align product mix, pricing and investment with coverage durability, clinical evidence and care-setting economics. FOR MANAGEMENT TEAMS Make Commercial Productivity Repeatable Improve active-account growth, reorder behaviour, sales-rep productivity and portfolio penetration while protecting processing yield. FOR BOARDS Test Build-Versus-Buy with Discipline Compare internal investment with adjacent products, tissue-processing capacity and channel access that complement the current platform.

  16. 16
    SECTION 06

    06

    06.

    Section 06 of 06 — The Full Universe, Methodology and Sources. Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 16

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    Full comparables table on EV/EBITDA (CY2027E) for the 8 approved companies, grouped by valuation tier.

    This table carries all 4 rated companies against the 10.0x sector median, with the 4 unrated names listed alongside them. Every row here is also in the companion workbook, which carries the complete field set. We keep this page as the reference point for any client who wants to check a specific name's basis.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (10.0x); amber marks below · 4 rated companies; 4 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 4 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥13.1x · median 16.7x · 1 companies LeMaitre Vascular, Inc. LMAT Graft delivery and soft-tissue repair instrumentation $1.7B 16.7x 10% 30% 43 CORE — 6.7x–13.1x · median 10.0x · 2 companies Artivion, Inc. AORT Regenerative implants and biologic scaffold devices $1.3B 11.9x 11% n/a 31 Integra LifeSciences Holdings Corporation IART Regenerative implants and biologic scaffold devices $3.0B 8.2x 3% 19% 25 DISCOUNT — <6.7x · median 2.3x · 1 companies SANUWAVE Health Inc. SNWV Energy- and device-assisted wound healing systems $50M 2.3x 26% 31% 60

  18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 1)

    All Precedent Transactions with Disclosed Terms, Newest First

    All Precedent Transactions with Disclosed Terms, Newest First.

    All Precedent Transactions with Disclosed Terms, Newest First 7 transactions with disclosed terms in this tier (23 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 26 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 16 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 1) All Precedent Transactions with Disclosed Terms, Newest First 7 transactions with disclosed terms in this tier (23 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 26 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 16 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jun-2025 Carisma Therapeutics Inc. → OrthoCellix, Inc. $135M n/a n/a The terminated OrthoCellix, Inc. proposal carried a recorded value of $135M. It separates announced consideration from a completed ownership change. May-2023 TowerBrook Capital Partners L.P. → Wound Business (TheraSkin and TheraGenesis) n/a n/a 6.0x TowerBrook Capital Partners L.P. agreed terms for Wound Business (TheraSkin and TheraGenesis) at 6.0x EV / EBITDA. The transaction suggests interest in an established wound platform with visible profit. Dec-2020 Integra LifeSciences Holdings Corporation → ACell, Inc. n/a 4.0x n/a Integra LifeSciences Holdings Corporation [IART] agreed to acquire ACell, Inc. at 4.0x EV / Revenue. The pairing suggests value in adding regenerative products to an existing surgical channel. Aug-2020 SANUWAVE Health, Inc. → Celularity, Inc. $23M 1.8x n/a SANUWAVE Health, Inc. [SNWV] acquired Celularity, Inc. for $23M at 1.8x EV / Revenue. The transaction joined wound-healing capabilities with a tissue-based product position. May-2019 3M Company → Acelity, Inc. $6.7B n/a 15.2x The Acelity, Inc. transaction established an upper-end benchmark for a scaled wound-care platform. Its size and profit valuation distinguish it from the smaller precedents. Dec-2016 Allergan plc → Acelity L.P. Inc. (LifeCell Corporation) n/a 6.4x n/a Allergan plc agreed to acquire Acelity L.P. Inc. (LifeCell Corporation) at 6.4x EV / Revenue. The transaction suggests strategic value in established tissue products and clinician access. Jun-2015 Integra LifeSciences Holdings Corporation → TEI Biosciences Inc., and TEI Medical Inc. n/a n/a 0.7x Integra LifeSciences Holdings Corporation [IART] acquired TEI Biosciences Inc., and TEI Medical Inc. at 0.7x EV / EBITDA. The result highlights the breadth of outcomes within regenerative assets.

  19. 19
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Methodology page explaining the sources, assumptions and data-quality treatment behind the report.

    This page sets out our sources, the valuation basis and the data-quality treatment applied throughout the report. Every figure links back to the record it was taken from, and where no link exists, the source and basis are named directly. It's the reference point for confirming any number used earlier in this deck.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice 19 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (4 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners also quote EV / Revenue in this industry; this set is profitable (median forward EBITDA margin 25%, 6 of 8 names with a meaningful EBITDA), so EV / EBITDA leads and EV / Revenue is the cross-check. EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Regenerative Medicine and it clears the coverage gate with 4 of 8 companies (50%). EV / Revenue, P / E are carried as a cross-check. The set earns: 4 of the 4 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 13 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 303 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (302) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  20. 20

    In This Set, Similar Margins Can Sit at Very Different Valuation Points.

    Closing slide restating that similar margins can sit at very different valuation points.

    We close on the same finding we opened with: similar margins can sit at very different valuation points. The companion tables carry the full universe, the exclusion ledger and the complete source index, so any figure in this deck can be traced further as a client sharpens its own view of the sector.

    Everything on this page

    In This Set, Similar Margins Can Sit at Very Different Valuation Points. NeuraCap AI — Regenerative Medicine Coverage September 2026 · Prepared by NeuraCap AI · Confidential Regenerative Medicine Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20

Sources and methodology

This report covers Regenerative Medicine (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Regenerative Medicine) with market data and consensus estimates as of September 28, 2026. The company universe is the 8 listed companies whose core business is Regenerative Medicine according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Artivion, Inc. (AORT), Integra LifeSciences Holdings Corporation (IART), LeMaitre Vascular, Inc. (LMAT), MiMedx Group, Inc. (MDXG), Organogenesis Holdings Inc. (ORGO), Sanara MedTech Inc. (SMTI), SANUWAVE Health Inc. (SNWV), Surrozen, Inc. (SRZN). The market map groups them by business vertical — Regenerative implants and biologic scaffold devices: 2 companies (IART, AORT); Graft delivery and soft-tissue repair instrumentation: 2 companies (LMAT, SMTI); Clinical-stage tissue regeneration therapeutics: 2 companies (MDXG, SRZN); Adjacent models: 2 companies (ORGO, SNWV). 4 of the 8 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Regenerative Medicine (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Regenerative Medicine) with market data and consensus estimates as of September 28, 2026. The company universe is the 8 listed companies whose core business is Regenerative Medicine according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Artivion, Inc. (AORT), Integra LifeSciences Holdings Corporation (IART), LeMaitre Vascular, Inc. (LMAT), MiMedx Group, Inc. (MDXG), Organogenesis Holdings Inc. (ORGO), Sanara MedTech Inc. (SMTI), SANUWAVE Health Inc. (SNWV), Surrozen, Inc. (SRZN). The market map groups them by business vertical — Regenerative implants and biologic scaffold devices: 2 companies (IART, AORT); Graft delivery and soft-tissue repair instrumentation: 2 companies (LMAT, SMTI); Clinical-stage tissue regeneration therapeutics: 2 companies (MDXG, SRZN); Adjacent models: 2 companies (ORGO, SNWV). 4 of the 8 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

13 records failed a validation gate and never feed a statistic in this report (12 excluded from aggregate; 1 quarantined). Each exclusion, with its reason: AORT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · IART — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MDXG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ORGO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ORGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ORGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · SMTI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · SNWV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · SRZN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · SRZN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · SRZN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · SRZN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · SRZN — Revenue for CY2026E is 3.1x the CY2025A value and 7.2x larger than CY2027E; the value is on a different basis from the periods either side of it and cannot be compared with them (effect: quarantined)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (4 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners also quote EV / Revenue in this industry; this set is profitable (median forward EBITDA margin 25%, 6 of 8 names with a meaningful EBITDA), so EV / EBITDA leads and EV / Revenue is the cross-check. EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Regenerative Medicine and it clears the coverage gate with 4 of 8 companies (50%). EV / Revenue, P / E are carried as a cross-check. The set earns: 4 of the 4 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 4 of 8 companies; EV / rEVenue: 8 of 8 companies; P/E: 6 of 8 companies. 2 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥13.1x, Core 6.7x–13.1x, Discount <6.7x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 10.0x = median(ev_ebitda CY2027E) (4 rated companies) · 16.7x = median(ev_ebitda CY2027E) within Premium tier (n=1) · 10.0x = median(ev_ebitda CY2027E) within Core tier (n=2) · 2.3x = median(ev_ebitda CY2027E) within Discount tier (n=1) · 39% = median Rule of 40 score (revenue growth + EBITDA margin) (n=3)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Regenerative Medicine recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 23 transactions were recorded for this industry; 7 are shown. 16 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 16 × deal value unit unresolved; 7 × no evidence record; 2 × duplicate precedent id; 1 × divestiture roles reassigned. Case studies lead with the 2 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 307 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Regenerative Medicine?

Company valuation reports run the same method against a single business — public or private.